All In Biotech

Drug Trial Radar · NCT03631771

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media

A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.

Last checked: Nov 20, 2026Latest source record: Apr 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 2022

Primary completion

Aug 2024

Study completion Feb 2025

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
Bayer; Guerbet/Liebel-Flarsheim
First posted
Aug 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, up to 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®) as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced diagnostic imaging procedure.

Conditions

  • Hypothyroidism

Interventions

  • IohexolDrug

    Iohexol administered intravascularly

  • IodixanolDrug

    Iodixanol administered intravascularly

  • IopromideDrug

    Iopromide administered intravascularly

  • IoversolDrug

    Ioversol administered intravascularly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects who develop hypothyroidism post-ICM.Time frame: 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.